Attorney Docket No. 54567.8001.US01

EXAMINER: MITRA, RITA

1653

1975

ART UNIT:

CONF:

CERTIFICATE OF MAILING

certify that this paper (along with any referred to as being attached or enclosed) is being redeposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 5, 2007 Rena Iov Date of Deposit

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: WANG, Chun et al.

APPLICATION NO.:

09/938,114

FILED:

August 23, 2001

FOR: AN ANTITHROMBOSIS ENZYME FROM

THE SNAKE VENOM OF AGKISTRODON

ACUTUS

STATEMENT OF SEQUENCE LISTING

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

Enclosed are a computer readable copy and a paper copy of the Sequence Listing for the above-identified patent application. The contents of both the computer readable and the paper copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

A sequence listing was submitted in the parent case of the present application, U.S. Patent Application No. 09/058,740, on June 30, 1998. This sequence listing appeared in the patent that issued from the parent case, U.S. Patent No. 6,489,451. The parent case sequence listing contains twelve sequences.

In a Submission of Sequence Listing filed October 5, 2001 in the present application, Applicants indicated that the sequence listing for the present application is identical to the computer readable sequence listing submitted in the parent application. As such, Applicants requested that the computer readable sequence listing from the parent application be used in the present application. However, when the present application published on January 30, 2003 as US-2003-0022350-A1, only eleven sequences were included in the sequence listing.

The sequence listing submitted herewith contains the same twelve sequences set forth in the parent case sequence listing. Although there are slight formatting differences between the present sequence listing and that of the parent case due to differences in the software used to create them, the sequences themselves are unchanged. As such, insertion of the present sequence listing into the present application adds no new matter.

Applicants have been informed that the present application has been allowed, and are currently awaiting issuance. Applicants believe that substitution of the published sequence listing with the sequence listing provided herewith will be sufficient to place the application in condition for issuance. If Applicants can do anything else to expedite issuance, please contact the undersigned at the address provided below.

Respectfully submitted, Perkins Coie LLP

Dated: March 5, 2007

By:

Patrick Morris, Ph.D. Registration No. 53,351

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900

Fax: (206) 332-7198